AU2001294834A1 - Recombinant bcg vaccines for the prevention and treatment of cancer - Google Patents

Recombinant bcg vaccines for the prevention and treatment of cancer

Info

Publication number
AU2001294834A1
AU2001294834A1 AU2001294834A AU9483401A AU2001294834A1 AU 2001294834 A1 AU2001294834 A1 AU 2001294834A1 AU 2001294834 A AU2001294834 A AU 2001294834A AU 9483401 A AU9483401 A AU 9483401A AU 2001294834 A1 AU2001294834 A1 AU 2001294834A1
Authority
AU
Australia
Prior art keywords
cancer
prevention
treatment
recombinant bcg
bcg vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294834A
Inventor
Helena R Chang
Maureen A. Chung
Michael A. O'donnell
Surendra Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Roger Williams Medical Center
Original Assignee
Beth Israel Deaconess Medical Center Inc
Roger Williams Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Roger Williams Medical Center filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2001294834A1 publication Critical patent/AU2001294834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001294834A 2000-09-26 2001-09-26 Recombinant bcg vaccines for the prevention and treatment of cancer Abandoned AU2001294834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23545500P 2000-09-26 2000-09-26
US60/235,455 2000-09-26
PCT/US2001/030346 WO2002026819A2 (en) 2000-09-26 2001-09-26 Recombinant bcg vaccines for the prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
AU2001294834A1 true AU2001294834A1 (en) 2002-04-08

Family

ID=22885578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294834A Abandoned AU2001294834A1 (en) 2000-09-26 2001-09-26 Recombinant bcg vaccines for the prevention and treatment of cancer

Country Status (4)

Country Link
US (1) US20020160502A1 (en)
AU (1) AU2001294834A1 (en)
CA (1) CA2424004A1 (en)
WO (1) WO2002026819A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
WO2003053459A2 (en) * 2001-12-10 2003-07-03 National Research Council Of Canada Differential induction, maintenance and regulation of cd8+ t cell response against a model antigen expressed by an acute versus a chronic intracellular bacterium
WO2003073828A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2003301114B2 (en) * 2002-12-31 2010-03-18 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
CN101967193B (en) * 2010-03-19 2016-03-30 上海医学生命科学研究中心有限公司 The Hsp60 fragment that can be combined with LOX-1, its derivative and application
PT2953634T (en) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Methods for expansion or depletion of t-regulatory cells
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN103602706B (en) * 2013-11-25 2015-07-15 河南省华隆生物技术有限公司 MUC1 (Mucins 1) and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) dual-gene co-expression recombinant vector and preparation method and application thereof
EA201692025A1 (en) 2014-05-21 2017-05-31 Университет Базель DELIVERY OF PROTEINS, BASED ON BACTERIA
US10130663B2 (en) * 2015-02-11 2018-11-20 The John Hopkins University Bacteria over-expressing c-di-AMP and therapeutic methods
EP3447075B1 (en) 2015-05-15 2023-08-09 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
EP3377094B1 (en) 2015-11-19 2021-04-28 Universität Basel Virulence attenuated bacteria for treatment of malignant solid tumors
AU2016355975B2 (en) 2015-11-19 2022-12-08 Universität Basel Bacteria-based protein delivery
KR20220088515A (en) 2016-05-13 2022-06-27 더 제너럴 하스피탈 코포레이션 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP7249279B2 (en) 2016-12-07 2023-03-30 サルスペラ，リミティド ライアビリティ カンパニー Synergistic treatment methods for cancer
DK3559022T3 (en) * 2016-12-20 2021-09-27 Univ Basel VIRULENCE WEAKENED BACTERIA - BASED PROTEIN DELIVERY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
US20020160502A1 (en) 2002-10-31
CA2424004A1 (en) 2002-04-04
WO2002026819A3 (en) 2003-01-16
WO2002026819A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2002336760A1 (en) Mutable vaccines
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU715620C (en) Therapeutic methods and uses
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002234773A1 (en) Pharmaceutically effective ginsenosides and their use
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU3755999A (en) Proteins that direct the secretion of virulence proteins and vaccines comprisingthem
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2001288795A1 (en) Eia vaccine and diagnostic
AU2001245939A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001259160A1 (en) Compositions and methods for the identification, assessment, prevention, and therapy of human cancers